Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRAJ33 is a joining (J) gene segment in the human T cell receptor alpha locus (TRA), encoding part of the TCR alpha chain's variable region via somatic V(J) recombination. TRAJ33 is particularly important as the canonical J segment in the TCR alpha chains of MAIT (mucosal-associated invariant T) cells—an innate-like T cell population that recognizes vitamin B metabolites presented by MR1. MAIT cell TCRs typically use TRAV1-2 (V gene) paired with TRAJ33, forming a semi-invariant TCR necessary for their antigen recognition and development[4]. During T cell development, TRAJ33 recombines with variable segments to generate diversity and specificity in TCRs expressed on the surface of MAIT cells. TRAJ33 is not a protein product, receptor, transporter, or enzyme on its own, but a genetic segment required for the assembly of functional TCR alpha chains[3][4].\n\nIf you need structured data extraction for MAIT cell TCR, that would relate to the combined TRAV1-2/TRAJ33 TCR alpha chain usage, which constitutes a semi-invariant receptor crucial for MAIT cell biology[4]. However, TRAJ33 alone should be classified as a gene segment, not a receptor or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 33 (TRAJ33).